PFA
HZNP

Pure Financial Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Pure Financial Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,925
Closed -$570K – 315
2023
Q3 		$570K Buy
+4,925
New +$529K 0.02% 163

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Pure Financial Advisors's HZNP Position: Q4 2023 in Review

Pure Financial Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 4,925 shares — an estimated $570K sold.

Pure Financial Advisors first reported a position in HZNP in Q3 2023 and held it in 1 quarter. The position peaked at $570K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Pure Financial Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Pure Financial Advisors sold 4,925 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $570K.
  • Pure Financial Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2023 and held it in 1 quarter.
  • Pure Financial Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $570K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Pure Financial Advisors's 13F filing for Q4 2023, filed 8 Jan 2024.